Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 46.17m |
Free float | 45.18m |
P/E (TTM) | -- |
Market cap | 786.33m USD |
EPS (TTM) | -2.15 USD |
Data delayed at least 15 minutes.
More ▼
- Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
- Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
- Pacira BioSciences Reports Third Quarter 2024 Financial Results
- Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
- Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
- Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
- Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
- Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
More ▼